Aging is associated with a disturbance in the regulation of the hypothalamic-pituitary-adrenal axis (HPA) and reduced levels of glucocorticoid receptors (GR) in the hippocampus. To compensate for these effects, we have investigated whether estrogen therapy normalized the HPA response to stress and GR in hippocampus and paraventricular (PVN) nucleus. Young (3–4 months) and old (20 months) male Sprague-Dawley rats were bled by tail cut in the basal state and following ether stress. While basal and ether-stimulated levels of plasma corticosterone (CORT) were similar in the two groups, old animals presented a delayed termination of the response to ether stress. A dexamethasone inhibition test carried out in old animals, showed a failure to completely block plasma CORT after ether stimulation. Furthermore, in old rats GR-immunoreactive levels were reduced in CA1-CA2 hippocampal subfields and subiculum, while normal levels were obtained in CA3-CA4 and PVN. We observed that prolonged estrogen treatment (6 weeks) of old rats normalized the termination of the stress response, restored dexamethasone inhibition of plasma CORT, and increased GR immunoreactivity in CA1 and CA2 hippocampal subfields and subiculum. The results suggest that estrogen treatment enhanced the glucocorticoid feedback signal by increasing GR in hippocampus, and corrected the disturbances in HPA axis regulation. These animal experiments may be important to elucidate the effects of estrogenic on the hippocampal and HPA dysfunction associated with aging and Alzheimer’s disease in humans.

Keywords:
Adrenal steroid receptors, Adrenal steroids, Hippocampus, Aging, Stress, Gonadal steroids, Corticotropin
1.
Lanfield PW, Waymire JC, Lynch G: Hippocampal aging and adrenocorticoids: quantitative correlations. Science 1978;202:1098–1101.
2.
Sapolsky R, Krey LC, McEwen BS: The neuroendocrinology of stress and aging: The glucocorticoid cascade hypothesis. Endocr Rev 1986;7:284–304.
3.
Sonntag WE, Goliszek AG, Brodish A, Eldridge JE: Diminished diurnal secretion of adrenocorticotropin (ACTH) but not corticosterone, in old male rats: Possible relation to increased adrenal sensitivity to ACTH in vivo. Endocrinology 1987;120:2308–2315.
4.
Issa A, Rowe W, Gauthier S, Meaney M: Hypothalamic-pituitary-adrenal activity in aged, cognitively unimpaired rats. J Neurosci 1990;10:3247–3254.
5.
Lorens SA, Hata N, Handa RJ, Van der Kar LD, Guschwan M, Goral J, Lee JM, Hamilton ME, Bethea CL, Clancy J: Neurochemical, endocrine and immunological responses to stress in young and old Fischer 344 male rats. Neurobiol Aging 1990;11:139–150.
6.
Pfeiffer A, Barden N, Meaney MJ: Age-related changes in glucocorticoid receptor binding and mRNA levels in the rat brain and pituitary. Neurobiol Aging 1991;12:475–479.
7.
Sapolsky R: Do glucocorticoid concentrations rise with age in the rat? Neurobiol Aging 1991;13:171–174.
8.
Van Eekelen JAM, Rots NY, Sutanto W, de Kloet ER: The effect of aging on stress responsiveness and central corticosteroid receptors in the Brown Norway rat. Neurobiol Aging 1991;13:159–170.
9.
Cizza G, Calogero AE, Brady LS, Bagdy G, Bergamini E, Blackman MR, Chrousos GP, Gold PW: Male Fischer 344/N rats show a progressive central impairment of the hypothalamic-pituitary-adrenal axis with advancing age. Endocrinology 1994;134:1611–1620.
10.
Morano MI, Vazquez DM, Akil H: The role of the hippocampal mineralocorticoid and glucocorticoid receptors in the hypothalamo-pituitary-adrenal axis of the aged Fischer rat. Mol Cell Neurosci 1994;5:400–412.
11.
Cai A, Wise PM: Age-related changes in the diurnal rhythm of CRH gene expression in the paraventricular nuclei. Am J Physiol 1996;33:E238–E243.
12.
Reul JMHM, de Kloet ER: Two receptor systems for corticosterone in rat brain: Microdistribution and differential occupation. Endocrinology 1985;117:2505–2511.
13.
McEwen BS, Cameron H, Chao HM, Gould E, Magariños AM, Watanabe Y, Wooley CS: Adrenal steroid and plasticity of hippocampal neurons: Toward an understanding of underlying cellular and molecular mechanisms. Cell Mol Neurobiol 1993;13:457–482.
14.
Tornello S, Orti E, De Nicola AF, Rainbow TC, McEwen BS: Regulation of glucocorticoid receptors in brain by corticosterone treatment of adrenalectomized rats. Neuroendocrinology 1982;35:411–417.
15.
Watanabe Y, Gould E, McEwen BS: Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res 1992;588:341–345.
16.
Woolley CS, Gould E, McEwen BS: Exposure to excess gluocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons. Brain Res 1990;531:225–231.
17.
Lanfield P, Eldridge C: Increased affinity of type II corticosteroid binding in aged rat hippocampus. Exp Neurol 1989;106:110–113.
18.
Rachmanin G, Lutge W, Hunter B, Walker D: Neither chronic exposure to ethanol nor aging affects type I or type II corticosteroid receptors in rat hippocampus. Exp Neurol 1989;106:164–171.
19.
McEwen BS: Re-examination of the glucocorticoid hypothesis of stress and aging. Progr Brain Res 1992;93:365–383.
20.
Seckl JR, Olsson T: Glucocorticoid hypersecretion and the age-impaired hippocampus. J Endocrinol 1995;145:201–211.
21.
Weiland NG, Orisaka C, Hayashi S, McEwen BS: Distribution and hormone regulation of estrogen receptor immunoreactive cells in the hippocampus of male and female rats. J Comp Neurol 1997;388:603–612.
22.
Kuiper GGJ, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustaffson J-A: Comparison of the ligand bindings specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997;138:863–870.
23.
Shugrue PJ, Lane MV, Merchenthaler I: Comparative distribution of estrogen receptor-α and -β mRNA in the rat central nervous system. J Comp Neurol 1997;388:507–525.
24.
Gould E, Wooley CS, Frankfurt M, McEwen BS: Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci 1990;10:1286–1291.
25.
Woolley CS, McEwen BS: Estradiol regulated hippocampal dendritic spine density via an N-metyl-D-aspartate receptor-dependent mechanism. J Neurosci 1994;14:7680–7687.
26.
Henderson V: The epidemiology of estrogen replacement therapy and Alzheimer’s disease. Neurology 1997;48(suppl 7):S27–S35.
27.
Goodman Y, Bruce AJ, Cheng B, Mattson MP: Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochem 1996;66:1836–1844.
28.
Behl C, Widmann M, Trapp T, Holsboer F: 17β-Estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 1995;216:473–482.
29.
Regan RF, Guo Y: Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures. Brain Res 1997;764:133–140.
30.
Viau V, Meaney MJ: Variations in the hypothalamic-pituitary-adrenal response to stress during the estrous cycle in the rat. Endocrinology 1991;129:2503–2511.
31.
Pfeiffer A, Lapointe B, Barden N: Hormonal regulation of type II gluocorticoid receptor messenger ribonucleic acid in rat brain. Endocrinology 1991;129:2166–2174.
32.
Redei E, Li L, Halasz I, McGivern RF, Aird F: Fast glucocorticoid feedback inhibition of ACTH secretion in the ovariectomized rat: Effect of chronic estrogen and progesterone. Neuroendocrinology 1994;60:113–126.
33.
Ferrini M, De Nicola AF: Estrogens up-regulate type I and type II glucocorticoid receptors in brain regions from ovariectomized rats. Life Sci 1991;48:2593–2601.
34.
Ferrini M, Lima A, De Nicola AF: Estradiol abolishes down-regulation of glucocorticoid receptors in brain. Life Sci 1995;57:2403–2412.
35.
Ferrini M, Grillo C, Piroli G, de Kloet ER, De Nicola AF: Sex differences in glucocorticoid regulation of vasopressin mRNA in the paraventricular hypothalamic nucleus. Cell Mol Neurobiol 1997;17:671–686.
36.
Lindheim SR, Legro RS, Bernstein L: Behavioral stress responses in premenopausal and postmenopausal women and the effects of estrogen. Am J Obstet Gynecol 1992;167:1831–1836.
37.
Meites J, Nicoll CS: Adenohypophysis prolactin. Ann Rev Physiol 1966;28:57–88.
38.
Weisenberg L, Fridman O, Libertun C, De Nicola AF: Changes in nuclear translocation of estradiol-receptor complex in anterior pituitary and uterus of rats with streptozotocin diabetes. J Steroid Biochem Mol Biol 1983;19:1737–1741.
39.
Magariños AM, Somoza G, De Nicola AF: Glucocorticoid negative feedback and glucocorticoid receptors after hippocampectomy in rats. Horm Metab Res 1987;19:105–109.
40.
Piroli G, Grillo C, Lux de Lantos V, Libertun C, De Nicola AF: Glucocorticoid receptors and inhibition of serum prolactin by dexamethasone are reduced in rats with estrogen-induced pituitary tumors. Neuroendocrinol Lett 1991;13:75–81.
41.
Fuxe K, Wikstrom AC, Okret S, Agnati LF, Harfstrand A, Yu Z-Y, Granholm L, Zoli M, Vale W, Gustafsson J-A: Mapping of glucocorticoid receptor immunoreactive neurons in the rat tel- and diencephalon using a monoclonal antibody against rat liver glucocorticoid receptor. Endocrinology 1985;117:1803–1812.
42.
Van Eekelen JAM, Kiss JZ, Westphal HM, de Kloet ER: Immunocytochemical study on the intracellular localization of the type 2 glucocorticoid receptor in the rat brain. Brain Res 1987;436:120–128.
43.
Herman JP, Schafer MKH, Young A, Thompson R, Douglas J, Akil H, Watson SJ: Evidence for hippocampal regulation of neuroendocrine neurons of the hypothalamo-pituitary-adrenocortical axis. J Neurosci 1989;9:3072–3082.
44.
Hatzinger M, Reul JMHM, Landgraf R, Holsboer F, Neumann I: Combined dexamethasone/CRH test in rats: Hypothalamo-pituitary-adrenocortical system alterations in aging. Neuroendocrinology 1996;64:349–356.
45.
O’Brien JT, Schweitzer I, Ames D, Tuckwell V, Mastwyck M: Cortisol suppression by dexamethasone in the healthy elderly: Effects of age, dexamethasone levels, and cognitive function. Biol Psychiatry 1994;36:389–394.
46.
Wilkstrom A-N, Bakke O, Okret S, Bronnegard M, Gustafsson J-A: Intracellular localization of the glucocorticoid receptor: Evidence for cytoplasmic and nuclear localization. Endocrinology 1987;120:1232–1242.
47.
Patchev V, Hayashi S, Orikasa C, Almeida OFX: Implications of estrogen-dependent brain organization for gender differences in hypothalamo-pituitary-adrenal regulation. FASEB J 1995;9:419–423.
48.
Turner BB: Sex differences in the binding of Type I and Type II corticosteroid receptors in rat hippocampus. Brain Res 1992;581:229–236.
49.
Turner BB: Influence of gonadal steroid on brain corticosteroid receptors: A minireview. Neurochem Res 1997;22:1375–1385.
50.
Luine VN: Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985;89:484–490.
51.
Gibbs R: Effects of estrogens on basal forebrain cholinergic neurons vary as a function of dose and duration of treatment. Brain Res 1997;757:10–16.
52.
Yau JLW, Dow RC, Fink G, Seckl JR: Medial septal lesions increase hippocampal mineralocorticoid and glucocorticoid receptor messenger RNA expression. Brain Res 1992;577:155–160.
53.
De Kloet ER: Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 1991;12:95–164.
54.
Oxenkrug GF, Pomara N, McIntyre IM, Branconier RJ, Staley M, Gershon S: Aging and cortisol resistance to suppression by dexamethasone: A positive correlation. Psychiatry Res 1983;10:125–130.
55.
De Leon MJ, Mcrae T, Tsai JR, George AE, Marcus DL, Freedman M, Wolf AP, McEwen BS: Abnormal cortisol response in Alzheimer’s disease linked to hippocampal atrophy. Lancet 1988;ii:391–392.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.